
CVS Health
CVS · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $114 bn
- Div. yield
- 3,5%
- Year to date
- +12,6%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
6 ✓ · 3 — · 0 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 10,4 | 16,7 | 25,1 |
| Forward P/E | 10,7 | — | 16,2 |
| PEG | 1,8 | — | 2,2 |
| P/S | 0,3 | 0,3 | 2,2 |
| EV/EBITDA | 10,8 | 14,3 | 17,3 |
| P/FCF | 7,3 | — | 19,5 |
| P/B | 1,4 | 1,3 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 32 analysts
- Buy
- 28
- Hold
- 4
- Sell
- 0
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 1,67 | 2,09 | Up +25,2% |
| Q2 2026 | 1,87 | 2,58 | Up +38,0% |
| Q1 2026 | 2,22 | 2,57 | Up +15,8% |
| Q4 2025 | 1,00 | 1,09 | Up +8,8% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108 bn | 106 bn | 100 bn | 106 bn | 103 bn | 98,9 bn | 94,6 bn | 97,7 bn | 95,4 bn | 91,2 bn | 88,4 bn | 93,8 bn |
| EPS | 1,68 | 2,31 | 2,30 | 2,32 | −3,13 | 0,80 | 1,41 | 1,31 | 0,07 | 1,41 | 0,88 | 1,59 |
| Margin | 2,0% | 2,8% | 2,9% | 2,8% | −3,9% | 1,0% | 1,9% | 1,7% | 0,1% | 1,9% | 1,3% | 2,2% |
| FCF | 3,91 bn | 5,65 bn | 3,40 bn | 2,61 bn | 98,0 m | 1,29 bn | 3,81 bn | 1,09 bn | −1,42 bn | 2,45 bn | 4,20 bn | −3,55 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $2,00 m (1 person), sales $324 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| shah prem s6 Nov 2026 · open-market purchase | $2,00 m | 23 855 | $83,90 |
| robbins larry21 May 2026 · sale | $34,6 m | 370 462 | $93,45 |
| robbins larry20 May 2026 · sale | $77 026 | 800 | $96,28 |
| robbins larry20 May 2026 · sale | $6,40 m | 66 881 | $95,67 |
| robbins larry20 May 2026 · sale | $14,5 m | 152 691 | $94,81 |
| robbins larry20 May 2026 · sale | $74,6 m | 797 628 | $93,48 |
| robbins larry19 May 2026 · sale | $14 372 | 151 | $95,18 |
| robbins larry19 May 2026 · sale | $187 m | 1 983 387 | $94,45 |
| mandadi tilak8 May 2026 · sale | $6,23 m | 69 551 | $89,58 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 1 Oct 1952
- Website
- cvshealth.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
SYKStryker Corporation | $310,72 | 72★★★★★★★★★would consider | 33,0 | +7,9% | 13,8% |
HCAHCA Healthcare | $511,78 | 69★★★★★★★★★would watch | 15,4 | +5,8% | 8,6% |
MCKMcKesson | $1 105,04 | 72★★★★★★★★★would consider | 27,3 | +8,2% | 1,1% |
MDTMedtronic | $102,88 | 78★★★★★★★★★would consider | 25,1 | +9,8% | 13,9% |
ELVElevance Health | $446,28 | 78★★★★★★★★★would consider | 18,1 | +3,6% | 2,5% |
Ratio — a score by our methodology, not an investment recommendation.




